Stockreport

Pharvaris Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Pharvaris N.V. - Ordinary Shares  (PHVS) 
PDF Enrollment completed in CHAPTER-3, a pivotal study of deucrictibant XR for prophylactic treatment of HAE attacks; topline data anticipated in 3Q2026Timeline for submissi [Read more]